Eticovo (etanercept-ykro) News

12 3 »

|||||||||| Eticovo (etanercept-ykro) / Biogen, Organon, Samsung, Ewopharma, Yuhan Corp, Mundipharma, Bionovis
Journal: Bone Morphogenetic Protein Signaling Agonist SB4 (BMPSB4) Inhibits Corticotroph Pituitary Neuroendocrine Tumors by Activation of Autophagy via a BMP4/SMADs-Dependent Pathway. (Pubmed Central) - Jul 18, 2024
BMPSB4 activates autophagy through a SMADs-dependent pathway, which in turn promotes autophagy-mediated cell death. Our work further elucidates the mechanism of the BMP4 signaling pathway in CD and suggests broad prospects for the development and application of BMPSB4 in CD therapy.

|||||||||| Erelzi (etanercept-szzs) / Sandoz
Journal: Charting the Etanercept Journey: Tracing Cost Dynamics in Poland's Off-Patent Market from Reference Drug Rivalry to Biosimilar Monopoly. (Pubmed Central) - Jul 14, 2024
This nation-level scenario of market re-monopolization by a biosimilar drug confirms net loss and excess costs for the healthcare payer, as can be expected from economic theory. The upwards drug repricing and restriction of treatment availability occurs much more rapidly than the decrement in a period of market competition.

|||||||||| Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo, Eticovo (etanercept-ykro) / Biogen, Organon, Samsung, Ewopharma, Yuhan Corp, Mundipharma, Bionovis
PK/PD data, Journal: Population Pharmacokinetic Analysis and Simulation of Alternative Dosing Regimens for Biosimilars to Adalimumab and Etanercept in Patients with Rheumatoid Arthritis. (Pubmed Central) - Jun 27, 2024
A simulation of dosing the etanercept biosimilar at a lower rate of every 10 days reached steady-state concentrations earlier than the usual dosing rate of every 7 days. Simulations of altered dosing intervals could form the basis for future personalised dosing studies, potentially saving costs whilst increasing efficacy.

|||||||||| Eticovo (etanercept-ykro) / Biogen, Organon, Samsung, Ewopharma, Yuhan Corp, Mundipharma, Bionovis
TRANSITIONING BACK AND FORTH BETWEEN BIO-ORIGINATOR ETANERCEPT AND BIOSIMILAR SB4 IN CLINICAL PRACTICE: IMPACT ON DRUG SURVIVAL AND DISEASE ACTIVITY () - May 29, 2024 - Abstract #EULAR2024EULAR_4051;
No significant differences were found between patients who previously had or had not used the bio-originator. Therefore, transitioning back and forth between biosimilar and bio-originator can be used in clinical practice to achieve cost-effective care.

|||||||||| Eticovo (etanercept-ykro) / Biogen, Organon, Samsung, Ewopharma, Yuhan Corp, Mundipharma, Bionovis
Preclinical, Journal: Effect of using scan body accessories and inter-implant distances on the accuracy of complete arch implant digital impressions: An in vitro study. (Pubmed Central) - Apr 10, 2024

|||||||||| hyoscine butylbromide oral / Generic mfg.
Preclinical, Journal: Vanillin derivatives as antiamnesic agents in scopolamine-induced memory impairment in mice. (Pubmed Central) - Feb 29, 2024
Therefore, transitioning back and forth between biosimilar and bio-originator can be used in clinical practice to achieve cost-effective care. The compounds; SB-1, SB-3, SB-4 and SB-6 more potently inhibited AChE with IC50 values of 0.078, 0.157, 0.108, and 0.014

|||||||||| Erelzi (etanercept-szzs) / Sandoz
Similar Treatment Adherence Between Individuals with Rheumatic Diseases Treated with Etanercept Originator and Biosimilar: a Population-Based Study () - Feb 8, 2024 - Abstract #CRAAHPA2024CRA_AHPA_153;
Low adherence is common among these patients but better in older individuals. Limitations of our analyses include our assumption that every individual was under same regimens and that reasons for nonadherence/treatment gaps are not available in claims data.

|||||||||| Erelzi (etanercept-szzs) / Sandoz, Hyrimoz (adalimumab-adaz) / Sandoz, Eticovo (etanercept-ykro) / Biogen, Organon, Samsung, Ewopharma, Yuhan Corp, Mundipharma
Clinical data, Journal: Forty-Eight-Month Monitoring of Disease Activity in Patients with Long-Standing Rheumatoid Arthritis Treated with TNF-? Inhibitors: Time for Clinical Outcome Prediction and Biosimilar vs Biologic Originator Performance. (Pubmed Central) - Jan 31, 2024
We conclude that biosimilars of adalimumab and etanercept have equivalent effectiveness over a long period of time compared to their originator drugs, and also that the levels of disease activity after 6 months of tumor necrosis factor-? inhibitors (originator drugs and biosimilars) might predict the response to therapy at 4 years in patients with long-standing rheumatoid arthritis.

|||||||||| Eticovo (etanercept-ykro) / Biogen, Organon, Samsung, Ewopharma, Yuhan Corp, Mundipharma
Journal: Copper(II)-photocatalyzed Hydrocarboxylation of Schiff bases with CO: antimicrobial evaluation and in silico studies of Schiff bases and unnatural ?-amino acids. (Pubmed Central) - Jan 9, 2024
In silico studies revealed strong binding strengths with E. faecalis DHFR (4M7U) for docked Schiff bases (SB) and unnatural ?-amino acids (UAAs). In vitro studies further demonstrated significant antimicrobial and antifungal activity for SB2, SB3, and SB4, while none of the synthesized UAAs exhibited such properties, primarily due to the electronic and binding properties of these molecules.Communicated by Ramaswamy H. Sarma.

|||||||||| Solymbic (adalimumab biosimilar) / Amgen, Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo, Eticovo (etanercept-ykro) / Biogen, Organon, Samsung, Ewopharma, Yuhan Corp, Mundipharma
Journal: Anti-tumor necrosis factor ?: originators versus biosimilars, comparison in clinical response assessment in a multicenter cohort of patients with inflammatory arthropathies. (Pubmed Central) - Dec 24, 2023
Real-life data demonstrated a similar safety profile between biosimilars and originators, but a reduced biosimilar retention rate at 24 months. Biosimilars could be considered a valid, safe, and less expensive alternative to originators, allowing access to treatments for a wider patient population.

|||||||||| Eticovo (etanercept-ykro) / Biogen, Organon, Samsung, Ewopharma, Yuhan Corp, Mundipharma
Preclinical, Journal: Influence of scanbody design and intraoral scanner on the trueness of complete arch implant digital impressions: An in vitro study. (Pubmed Central) - Dec 23, 2023
Biosimilars could be considered a valid, safe, and less expensive alternative to originators, allowing access to treatments for a wider patient population. Seven scanbodies (SB1, SB2, SB3, SB4, SB5, SB6, and SB7) and four intraoral scanners (Primescan

|||||||||| Eticovo (etanercept-ykro) / Biogen, Organon, Samsung, Ewopharma, Yuhan Corp, Mundipharma
Journal: Comparative Analysis of Anticonvulsant Activity of Trans and Cis 5,5'-Diphenylhydantoin Schiff Bases. (Pubmed Central) - Nov 29, 2023
Our results suggest that trans-cis conversion of 5,5'-diphenylhydantoin Schiff bases has potential against seizure spread in the MES test and mitigated the KA-induced SE. The antioxidant potency of cisSB4-Ph might be associated with its efficacy in mitigating the SE.

|||||||||| Eticovo (etanercept-ykro) / Biogen, Organon, Samsung, Ewopharma, Yuhan Corp, Mundipharma
Journal, HEOR: Comparative effectiveness of etanercept originator and biosimilar for treating rheumatoid arthritis: implications for cost-savings. (Pubmed Central) - Nov 28, 2023
Treatment persistence using either ETN originator or biosimilar was similar. The cost of all brands of ETN markedly reduced upon listing of the ETN biosimilar, resulting in significant savings for the Australian Government.

|||||||||| phenytoin / Generic mfg.
Journal: Additive Anticonvulsant Profile and Molecular Docking Analysis of 5,5'-Diphenylhydantoin Schiff Bases and Phenytoin. (Pubmed Central) - Nov 25, 2023
These data, combined with the worst interaction energies of our ligands with the mu receptor, suggest that the primary mechanism of their action involves the kappa and delta receptors, where the selectivity to the kappa receptor leads to higher biological effects. Our findings suggest that the four Schiff bases might be promising candidates with potential applications as a safe and effective adjuvant in epilepsy.

|||||||||| Hadlima (adalimumab-bwwd) / Organon, Biogen, Samsung, Mundipharma, Yuhan Corp, Eticovo (etanercept-ykro) / Biogen, Organon, Samsung, Ewopharma, Yuhan Corp, Mundipharma
Review: Healthcare Professional (HCP) and Patient Usability Evaluation and Preferences of Two Auto-injector Devices for Self-Injection of Biosimilars, SB4 and SB5: A Literature Review. (Pubmed Central) - Aug 24, 2023
Therefore, they were preferred over the other reference product autoinjectors. Because user-friendly devices can improve treatment adherence, pharmaceutical companies should consider patient convenience when developing medical devices.

|||||||||| Eticovo (etanercept-ykro) / Samsung, Merck (MSD), Ewopharma, Yuhan Corp, Mundipharma, Biogen
Review, Journal: Managing spot blotch disease in wheat: Conventional to molecular aspects. (Pubmed Central) - Mar 10, 2023
Despite, marker assisted breeding for SB resistance in wheat is scarce. Better understanding of wheat genome assemblies, functional genomics and cloning of resistance genes will further accelerate breeding for SB resistance in wheat.

|||||||||| Eticovo (etanercept-ykro) / Samsung, Merck (MSD), Ewopharma, Yuhan Corp, Mundipharma, Biogen
Journal: Effectiveness and Persistence in SB4 and Reference Etanercept-Treated Rheumatoid Arthritis Patients in Ordinary Clinical Practice in Norway. (Pubmed Central) - Feb 2, 2023
Better understanding of wheat genome assemblies, functional genomics and cloning of resistance genes will further accelerate breeding for SB resistance in wheat. Outcomes for disease status/drug persistence at W52 were similar between patients with RA treated with etanercept or SB4.

|||||||||| Eticovo (etanercept-ykro) / Samsung, Merck (MSD), Ewopharma, Yuhan Corp, Mundipharma, Biogen
Preclinical, Journal: How the geometry of the scan body affects the accuracy of digital impressions in implant supported prosthesis. In vitro study. (Pubmed Central) - Jan 6, 2023
The scan bodies PRMG (SB3) and TALL (SB4) lead to smaller errors in distance, projected height and angulation than ELOS (SB1) and MG (SB2)...Any marginal discrepancy may lead to the failure of the rehabilitation or the implant due to the associated biomechanical problems. Key words:IOS, CAD/CAM, SCAN Bodies.

|||||||||| Eticovo (etanercept-ykro) / Samsung, Merck (MSD), Ewopharma, Yuhan Corp, Mundipharma, Biogen
Observational data, Journal: Outcome of adult patients with JIA treated with the biosimilar Benepali: results of the biologic register JuMBO. (Pubmed Central) - Dec 16, 2022
Tolerability and effectiveness of the biosimilar Benepali were satisfactory and therapy survival was comparable to the originator. Further data on therapy with biologics and biosimilars such as Benepali must be collected by registries such as BiKeR and JuMBO in order to optimize therapy and patient outcomes and to reduce costs in the health system in the long term.

|||||||||| Eticovo (etanercept-ykro) / Samsung, Merck (MSD), Ewopharma, Yuhan Corp, Mundipharma, Biogen
P4 data, Journal, Real-world evidence: Safety and Effectiveness of Etanercept Biosimilar SB4 for Rheumatic Diseases in South Korea: Real-World Post-marketing Surveillance Data. (Pubmed Central) - Dec 10, 2022
Further data on therapy with biologics and biosimilars such as Benepali must be collected by registries such as BiKeR and JuMBO in order to optimize therapy and patient outcomes and to reduce costs in the health system in the long term. This first real-world evidence of SB4 from a phase IV PMS study in Korea shows comparable effectiveness to historical SB4 real-world evidence without any new significant safety signals.

|||||||||| Eticovo (etanercept-ykro) / Samsung, Merck (MSD), Ewopharma, Yuhan Corp, Mundipharma, Biogen
Journal: Effectiveness of SB4 Transition from Originator Etanercept in Rheumatoid Arthritis and Axial Spondyloarthritis: A Subgroup Analysis from the BENEFIT Study. (Pubmed Central) - Dec 6, 2022
Both the cohorts are representative of typical patients with long-standing established diagnoses. Most of the patients transitioned to the same dose regimen of biosimilar as that received for the originator, and the regimen remained unchanged at 6 months, supporting the effectiveness of the transition.

|||||||||| Eticovo (etanercept-ykro) / Samsung, Merck (MSD), Ewopharma, Yuhan Corp, Mundipharma, Biogen
Journal: First report of Curtobacterium flaccumfaciens pv. flaccumfaciens causing bacterial tan spot of soybean in Russia. (Pubmed Central) - Dec 6, 2022
Ten isolates (SB1 to SB4 from Stavropol, F-125-1 to F-125-3 from Ryazan, and F-30-1 to F-30-3 from Amur) were selected, and further identified by morphological, physiological, and biochemical properties, MALDI TOF MS, 16S rRNA sequences, and specific primers CffFOR2 and CffREV4 (Tegli et al...To the best of our knowledge, this is the first report of C. flaccumfaciens pv. flaccumfaciens causing a bacterial tan spot of soybean in Russia.

|||||||||| Eticovo (etanercept-ykro) / Samsung, Merck (MSD), Ewopharma, Yuhan Corp, Mundipharma, Biogen
Observational data, Journal: Post-switch Effectiveness of Etanercept Biosimilar Versus Continued Etanercept in Rheumatoid Arthritis Patients with Stable Disease: A Prospective Multinational Observational Study. (Pubmed Central) - Oct 5, 2022
flaccumfaciens causing a bacterial tan spot of soybean in Russia. SB4 demonstrated comparable effectiveness to ETN over 12 months in patients with stable RA who voluntarily switched to the biosimilar in a real-world setting.

|||||||||| Humira (adalimumab) / Eisai, AbbVie
Long-term Follow-up of Starting and Switching from Bio-originator to Biosimilar: Real-world Data in Axial Spondyloarthritis Patients Treated with Adalimumab and Etanercept (Virtual Poster Hall) - Sep 17, 2022 - Abstract #ACRConvergence2022ACR_CONVERGENCE_2026;
Response to treatment was also similar between groups. Drug survival in the three adalimumab groups (originator adalimumab – blue line, biosimilar adalimumab – red line, and switch from originator to biosimilar adalimumab – green line)Drug survival in the three etanercept groups (originator etanercept – blue line, biosimilar etanercept – red line, and switch from originator to biosimilar etanercept – green line)

|||||||||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical, Journal: Comparison of treatment retention of originator vs biosimilar products in clinical rheumatology practice in Sweden. (Pubmed Central) - Sep 10, 2022
Drug survival in the three adalimumab groups (originator adalimumab – blue line, biosimilar adalimumab – red line, and switch from originator to biosimilar adalimumab – green line)Drug survival in the three etanercept groups (originator etanercept – blue line, biosimilar etanercept – red line, and switch from originator to biosimilar etanercept – green line) This large observational study supports the equivalence of biologic DMARD biosimilar products and originators when used in routine rheumatology care.

|||||||||| Erelzi (etanercept-szzs) / Novartis
Journal: Effectiveness and safety of a biosimilar-to-biosimilar switch of the TNF inhibitor etanercept in patients with chronic inflammatory rheumatic diseases. (Pubmed Central) - Sep 3, 2022
The retention rate after switches from originator ETN to two ETN bsDMARD was close to 90%. Multiple switches resulted in a high adherence rate without clinically important efficacy or safety signals.

|||||||||| Eticovo (etanercept biosimilar) / Samsung, Merck (MSD), Ewopharma, Yuhan Corp, Mundipharma, Biogen
Journal: Biosimilar versus originator etanercept: a real-life clinical study. (Pubmed Central) - Aug 5, 2022
Multiple switches resulted in a high adherence rate without clinically important efficacy or safety signals. Overall, we can confirm the overlapping clinical efficacy between ETN and its biosimilar SB4 drug and that even in an uncontrolled environment such as real-life, the biosimilar drugs are an excellent opportunity to reduce health costs allowing to expand the audience of patients who can benefit from these innovative treatments.

|||||||||| Eticovo (etanercept biosimilar) / Samsung, Merck (MSD), Ewopharma, Yuhan Corp, Mundipharma, Biogen
Journal: Predicting Loss of Efficacy after Non-Medical Switching: Correlation between Circulating TNF-α Levels and SB4 in Etanercept to SB4 Switchers and Naïve Patients with Rheumatic Disease. (Pubmed Central) - Jul 29, 2022
Moreover, in naïve patients, DL and TNF-α levels were higher in NR than in NNR. Monitoring DL and TNF-α levels may represent a future precision medicine approach to predict loss of efficacy after NMS.

|||||||||| Eticovo (etanercept biosimilar) / Samsung, Merck (MSD), Ewopharma, Yuhan Corp, Mundipharma, Biogen
Observational data, Journal, Real-world evidence: Effectiveness and safety of original and biosimilar etanercept (Enbrel® vs Benepali®) in bDMARD-naïve patients in a real-world cohort of Portugal. (Pubmed Central) - Jul 17, 2022
Benepali® and Enbrel® demonstrated similar effectiveness and safety in RA, PsA and SpA in our cohort of patients. These data corroborate that the original and biosimilar drugs have similar quality characteristics and biological activity.

|||||||||| Eticovo (etanercept biosimilar) / Samsung, Merck (MSD), Ewopharma, Yuhan Corp, Mundipharma, Biogen
Review, Journal: TNFα inhibitor biosimilars associated with alopecia areata. Case-based review. (Pubmed Central) - May 26, 2022
In this report, we describe two patients, a 32-year-old woman with ankylosing spondylitis and a 48-year-old man with rheumatoid arthritis who were both treated with SB4 (Benepali), an etanercept biosimilar, and developed AA, 6 and 12 months respectively after the initiation of TNFα blocker biosimilar...Thus, physicians when dealing with patients treated with these agents, should be aware of possible immune skin reactions, among them AA. To this end, a close follow-up and monitoring is mandatory.

|||||||||| Humira (adalimumab) / Eisai, AbbVie
ANTI-TNFα: ORIGINATORS vs BIOSIMILARS, COMPARISON IN CLINICAL RESPONSE ASSESSMENT IN A MULTICENTER COHORT OF PATIENTS WITH INFLAMMATORY ARTHROPATHIES () - May 24, 2022 - Abstract #EULAR2022EULAR_3344;
Real-life data demonstrated the same safety between biosimilars and originators but a reduced biosimilar retention rate at 24 months, about 76%. Despite their loss efficacy, biosimilars could be considered valid and safe, and a good and less expensive alternative to the originators, allowing access to these innovative treatments to a wider patient population.

|||||||||| Eticovo (etanercept biosimilar) / Samsung, Merck (MSD), Ewopharma, Yuhan Corp, Mundipharma, Biogen
Journal: A comparison between BMP4 and SB4 in inducing germ line gene expression pattern during embryonic stem cells differentiation. (Pubmed Central) - May 6, 2022
Moreover, co-presence of both BMP4 and SB4 could increase the expression level of Prdm14, Nnose3 and Stella (Dppa3), and thereby improve establishment of the germ cell fate during in-vitro differentiation of embryonic stem cells. In summary, our data suggest that SB4 could improve germ line gene expression pattern induced by BMP4 during embryonic stem cells in-vitro differentiation.

|||||||||| Eticovo (etanercept biosimilar) / Samsung, Merck (MSD), Ewopharma, Yuhan Corp, Mundipharma, Biogen
Journal: High fiber content snack bars made with maize biomass flour, rice flakes and oat flakes: Physicochemical properties and sensory acceptance. (Pubmed Central) - Mar 8, 2022
SB4 (containing 14.85:5:10.85% of MBF:RF:OF, respectively) and SB6 (containing 14:8:8% of MBF:RF:OF, respectively) were the closest to the desirable formulation according to the desirability diagram for the physicochemical properties of the SBs...The SB6 presented the highest sensory acceptance and purchase intent, highlighting its rich content of dietary fiber (16.45 ± 0.1 g 100 g) and protein (7.04 ± 0.02 g 100 g) besides its low-calorie characteristic (1421.22 kJ 100 g/339.68 kcal 100 g). The development of SBs using MBF is feasible in relation to their physicochemical and sensory properties, which can stimulate the sustainable production of new goods from this by-product.

|||||||||| Eticovo (etanercept biosimilar) / Samsung, Merck (MSD), Ewopharma, Yuhan Corp, Mundipharma, Biogen
Clinical, Journal: Training Distribution During a Paralympic Cycle for a Multiple Swimming Champion With Paraplegia: A Case Report. (Pubmed Central) - Mar 3, 2022
The development of SBs using MBF is feasible in relation to their physicochemical and sensory properties, which can stimulate the sustainable production of new goods from this by-product. This case study exemplifies how a female Paralympic swimmer with paraplegia progressed her training in the seasons leading up to the Paralympic Games, reaching an annual training distance of 2000 km, which is similar to that of able-bodied swimmers.

|||||||||| Eticovo (etanercept biosimilar) / Samsung, Merck (MSD), Ewopharma, Yuhan Corp, Mundipharma, Biogen
Clinical: Texas law SB4 bans mail order pills and telehealth consultations for abortions, imposing fines and jail time. This violates a woman's right to access a medication that is effective at preventing pregnancy & has been deemed safe & appropriate by the FDA. https://t.co/J7BGPPJNmP (Twitter) - Feb 25, 2022

|||||||||| Eticovo (etanercept biosimilar) / Samsung, Merck (MSD), Ewopharma, Yuhan Corp, Mundipharma, Biogen
Journal: Efficacy and Drug Survival after Switching from Etanercept to the Biosimilar SB4: A Real-Life Long-Term Study. (Pubmed Central) - Feb 16, 2022
Forty-one (17.4%) patients left the study due to the interruption of the SB4 treatment, 31 (75.6%) discontinued due to inefficacy and 10 (24.4%) due to adverse events. This real-life study confirms the similar efficacy profile of ETA with long-term retention and a good safety profile in inflammatory arthritis patients.

|||||||||| Journal: Expanded Table: Some biologic drugs and JAK inhibitors for rheumatoid arthritis. (Pubmed Central) - Feb 8, 2022
This real-life study confirms the similar efficacy profile of ETA with long-term retention and a good safety profile in inflammatory arthritis patients. No abstract available

|||||||||| Erelzi (etanercept biosimilar) / Novartis
Retention and Tolerability of Mandated Biosimilar Switching for Etanercept and Infliximab at One Year: A Large Single-Centre Experience in British Columbia ([VIRTUAL]) - Feb 3, 2022 - Abstract #CRAAHPA2022CRA_AHPA_143;
Overall, switching from Enbrel and Remicade to an approved biosimilar as mandated by BC Pharmacare for rheumatology indications was well tolerated in this review, with 78% of patients remaining on their biosimilar one year after the policy was implemented. There were no significant differences in the odds of retention based on medication or disease type between rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.

|||||||||| Eticovo (etanercept biosimilar) / Samsung, Merck (MSD), Ewopharma, Yuhan Corp, Mundipharma, Biogen
Etanercept originator versus its biosimilar (SB4) for the treatment of rheumatoid arthritis. Are they truly similar? (Alsh 1) - Jan 30, 2022 - Abstract #BSR2022BSR_18;
There were no significant differences in the odds of retention based on medication or disease type between rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. This analysis is the first to our knowledge to show similar outcomes amongst biologic-naïve patients with RA treated with either ETN-O or ETN-B using real-world data, which brings further evidence for similarity between the drugs.

|||||||||| Eticovo (etanercept biosimilar) / Samsung, Merck (MSD), Ewopharma, Yuhan Corp, Mundipharma, Biogen
Outcomes after switching from etanercept originator to its biosimilar (SB4) for the treatment of rheumatoid arthritis (Alsh 1) - Jan 30, 2022 - Abstract #BSR2022BSR_17;
Among the sub-cohorts of patients who discontinued ETN-B, differences were observed regarding the frequency and reasons for treatment withdrawal. These results will support UK rheumatologists and patients with treatment decisions, assist quality improvement projects to reduce drug withdrawals and refine biologic treatment delivery in the UK.

|||||||||| Eticovo (etanercept biosimilar) / Samsung, Merck (MSD), Ewopharma, Yuhan Corp, Mundipharma, Biogen
Journal: Modulation of Double Zwitterionic Block Copolymer Aggregates by Zwitterion-Specific Interactions. (Pubmed Central) - Jan 28, 2022
The PCB2-b-PSB4 aggregates were dissociated by the addition of nondetergent sulfobetaine (SB4) and carboxybetaine (CB2) molecules, while the aggregates showed different aggregation modulation processes for SB4 and CB2...The PCB2-b-PSB4 aggregate modulation efficiency of SBs associated with the intercharge hydrocarbon spacer length (CSL) rather than the symmetry with the SB in the PSB chain. These zwitterion-specific modulation behaviors were rationalized based on the nature of zwitterions including partial charge density, dipole moment, and hydrophobic interactions depending on the charged groups and CSL.

|||||||||| Eticovo (etanercept biosimilar) / Samsung, Merck (MSD), Ewopharma, Yuhan Corp, Mundipharma, Biogen
Journal: Genetic Diversity and Population Structure of Sorghum [Sorghum Bicolor (L.) Moench] Accessions as Revealed by Single Nucleotide Polymorphism Markers. (Pubmed Central) - Jan 26, 2022
Hence, crossbreeding genotypes from different clusters and evaluating their progenies for desirable traits is advantageous. The exceptionally high heterozygosity observed in accession SB4 and SB21 from the western geographic region is an intriguing finding of this study, which merits further investigation.

|||||||||| Eticovo (etanercept biosimilar) / Samsung, Merck (MSD), Ewopharma, Yuhan Corp, Mundipharma, Biogen
Journal: Ultrastructure of the Sensilla on the Antennae and Mouthparts of Bean Weevils, Megabruchidius dorsalis (Coleoptera: Bruchinae). (Pubmed Central) - Dec 24, 2021
There were seven types and eight subtypes of antennal sensilla, including Bőhm bristles (BB), two subtypes of sensilla trichoid (ST1, ST2), two subtypes of sensilla chaetica (SC1, SC2), four subtypes of sensilla basiconic (SB1, SB2, SB3, SB4), sensilla cavity (SCa), sensilla auricillica (SA), and sensilla gemmiformium (SG)...We discussed potential function related to structure via comparisons with previous investigations of bruchids and other insects. Our results provide a theoretical basis for further studies on sensory physiological function, using semiochemicals as effective biological controls of M. dorsalis.

|||||||||| Eticovo (etanercept biosimilar) / Samsung, Merck (MSD), Ewopharma, Yuhan Corp, Mundipharma, Biogen
Clinical, Observational data, Journal, HEOR: Effectiveness, safety and economic analysis of Benepali in clinical practice. (Pubmed Central) - Dec 16, 2021
Our results provide a theoretical basis for further studies on sensory physiological function, using semiochemicals as effective biological controls of M. dorsalis. The biosimilar Benepali is as effective and safe as the original and much more cost-effective.

|||||||||| TNFcept (etanercept biosimilar) / LG Chem, Mochida
Retrospective data, Journal: Comparative efficacy and safety of etanercept biosimilars in comparison with etanercept in patients with rheumatoid arthritis who have insufficient response to methotrexate: A network meta-analysis. (Pubmed Central) - Nov 21, 2021
The biosimilar Benepali is as effective and safe as the original and much more cost-effective. No significant difference was found between etanercept biosimilars and etanercept originators in patients with active RA despite treatment with MTX in terms of the ACR20 response rate and SAEs.

|||||||||| Eticovo (etanercept biosimilar) / Samsung, Merck (MSD), Ewopharma, Yuhan Corp, Mundipharma, Biogen
Journal: Observation of the fine structure of antennal sensilla of the stink bug, Eocanthecona furcellata (Hemiptera: Pentatomidae). (Pubmed Central) - Oct 30, 2021
SB4 was found only on females and SCo2 was found only on males...The morphology and putative functions of each sensilla were compared and discussed. These results provide a reference for further study of the behavioral biology, chemical ecology and electrophysiology of insects, and also provides a scientific basis for new ways of biological control.

|||||||||| Journal: Uptake of biosimilars for TNF-α inhibitors adalimumab and etanercept following the best-value biological medicine initiative in Ireland. (Pubmed Central) - Oct 20, 2021
The gain-share prescribing incentive has raised over €3.6 million for the specialties to invest back into patient care. Conclusion Against the background of a finite healthcare budget, this study shows that increasing use of biosimilars can create the financial savings and space to invest in new innovative therapies for the benefit of many patients.

|||||||||| Eticovo (etanercept biosimilar) / Samsung, Merck (MSD), Ewopharma, Yuhan Corp, Mundipharma, Biogen
Journal: Doctor's aptitude for switching from innovator etanercept to biosimilar etanercept in inflammatory rheumatic diseases: experience from a single French rheumatology tertiary care center. (Pubmed Central) - Sep 24, 2021
Conclusion Against the background of a finite healthcare budget, this study shows that increasing use of biosimilars can create the financial savings and space to invest in new innovative therapies for the benefit of many patients. The probability of switching from iETN to bETN was likely related to physician characteristics.

|||||||||| Eticovo (etanercept biosimilar) / Samsung, Merck (MSD), Ewopharma, Yuhan Corp, Mundipharma, Biogen
[VIRTUAL] A Non-Interventional Prospective Observational Study of Treatment with Etanercept Biosimilar (SB4) in Rheumatoid Arthritis in Real Life Clinical Practice; Interim Analysis of the ‘BENEFICIAL’ Study () - Sep 21, 2021 - Abstract #ACRCONVERGENCE2021ACR_CONVERGENCE_1124;
The probability of switching from iETN to bETN was likely related to physician characteristics. These are the first real-world data on SB4 in a routine setting in Greece, indicating that the majority of patients in this study cohort demonstrated clinically meaningful improvement in their physical function and disease activity by 24 and 52 weeks post-initiation of SB4 for treatment of RA.

|||||||||| Erelzi (etanercept biosimilar) / Novartis, Eticovo (etanercept biosimilar) / Samsung, Merck (MSD), Ewopharma, Yuhan Corp, Mundipharma, Biogen
Clinical, Journal: Cross-Switch from Etanercept Originator to Biosimilar SB4 and to GP2015 in Patients with Chronic Plaque Psoriasis. (Pubmed Central) - Aug 22, 2021
These are the first real-world data on SB4 in a routine setting in Greece, indicating that the majority of patients in this study cohort demonstrated clinically meaningful improvement in their physical function and disease activity by 24 and 52 weeks post-initiation of SB4 for treatment of RA. No abstract available



	Diseases Companies Products Productz Mechanisms of Action Sites